Oncology Clinical Trials

Oncology remains the therapeutic area with the most drug failures, the lowest numbers of patients enrolled and the highest with the number of drugs in clinical trials. Many trends in oncology clinical trials seek to address these challenges and include the use of biomarkers, immunotherapies, and adaptive designs.

.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

© Africa Studio - © Africa Studio - stock.adobe.com

FDA Approves UCB’s Kygevi for TK2 Deficiency Based on Multi-Study Clinical Program Demonstrating Significant Survival and Motor Gains

ByAndy Studna, Senior Editor

November 5th 2025

Oncology Clinical Trials

Newsletter

Related Content

Novo Nordisk’s Phase III OASIS 4 Analyses Highlight Cardiometabolic Benefits of Oral Semaglutide 25 mg

Eli Lilly’s Phase II Trial of Eloralintide Shows Up to 20% Weight Reduction in Adults With Obesity

ACT Brief: Data Strategy, AI Integration, and Rare Disease Milestones Drive Clinical Innovation

Designing Feasible Protocols with Real-World Data

FDA Approves UCB’s Kygevi for TK2 Deficiency Based on Multi-Study Clinical Program Demonstrating Significant Survival and Motor Gains

Trending on Applied Clinical Trials Online

Eli Lilly’s Phase II Trial of Eloralintide Shows Up to 20% Weight Reduction in Adults With Obesity

Novo Nordisk’s Phase III OASIS 4 Analyses Highlight Cardiometabolic Benefits of Oral Semaglutide 25 mg

FDA Approves UCB’s Kygevi for TK2 Deficiency Based on Multi-Study Clinical Program Demonstrating Significant Survival and Motor Gains

Designing Feasible Protocols with Real-World Data

Inside the Recruitment Bottlenecks Driving Trial Delays